Fig. 5. Effects of VEGF receptor inhibitors injected intracisternally on formalin-induced nociceptive behavior. Intracisternal pretreatment with ZM306416 (100 μg), a VEGF type 1 receptor inhibitor, or vandetanib (20 μg), a VEGF type 2 receptor inhibitor, attenuated formalin-induced scratching behavior in the second phase. There were six animals in each group. *p<0.05, VEGF receptor inhibitors- vs. vehicle-treated group.
© Oral Biol Res
